Cellebrite DI (CLBT) Earnings Analysis
Cellebrite DI (CLBT) next reports earnings on 2026-08-13, consensus EPS 0.0739 USD. Last quarter (2026-05-14) it missed with EPS 0.04 USD vs 0.05377 USD est (-25.6%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 48.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CLBT next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | 0.0739 USD |
| Revenue estimate | 0.13B |
CLBT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 0.04 USD | 0.05377 USD | -25.6% | Miss |
| 2025-11-12 | 0.14 USD | 0.09449 USD | +48.2% | Beat |
| 2025-08-14 | 0.12 USD | 0.1 USD | +20% | Beat |
| 2025-02-13 | 0.1 USD | 0.1 USD | 0% | Beat |
| 2024-08-15 | 0.1 USD | 0.08 USD | +25% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
CLBT valuation and analyst view
| Trailing P/E | 48.55 |
|---|---|
| Trailing EPS | 0.29157 USD |
| Price / book | 6.85 |
| Dividend yield | 0.00% |
| Market cap | 3.56B |
| Analyst consensus | Buy (8 buy / 0 hold / 0 sell) |
| Avg price target | 17.5 USD |
Related research pages
Frequently asked questions
When is Cellebrite DI (CLBT)'s next earnings date?
Cellebrite DI is next scheduled to report on 2026-08-13, with a consensus EPS estimate of 0.0739 USD and revenue estimate of 0.13B.
Did CLBT beat earnings last quarter?
In its 2026-05-14 report, CLBT posted EPS of 0.04 USD versus a 0.05377 USD estimate — a miss of 25.6%.
What is CLBT's earnings track record?
Over the last 5 reported quarters with consensus data, CLBT beat estimates 4 times (80%).
What is CLBT's current P/E ratio and EPS?
CLBT trades at a trailing P/E of 48.55 on trailing EPS of 0.29157291154248155 USD.
What do analysts rate CLBT?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 17.5 USD.